---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-24-000005"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:56:45.596607+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML

## Summary
- Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.
- Cash at Dec 31, 2023: $2.5M; subsequent $9M (Jan) and $20M (Mar 2024) raised.
- Phase 2a SLS009 in r/r AML: 50% response at 30mg BIW optimal dose; 100% in biomarker patients.
- Phase 3 REGAL (GPS) enrollment completed; IDMC meeting late April; interim analysis possible in 1H2024.
- Phase 1b/2 SLS009 in PTCL top-line data expected 1H2024; first DLBCL combo patient dosed.

## SEC filing metadata
- accession: 0001390478-24-000005
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/0001390478-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/sls-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-24-000005
- JSON: https://secwatch.observer/filing/0001390478-24-000005.json
- Plain text: https://secwatch.observer/filing/0001390478-24-000005.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/0001390478-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.